Roche and Hansoh Enter Cancer-Therapy Licensing Deal Worth Up to $15 Billion
Roche Holding entered a collaboration and licensing agreement with Hansoh Pharmaceutical Group centered on cancer therapies. The deal could net Hansoh more than $15 billion.